Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05486715

Acronym

Vitamind

Enrollment

130

Registered

2022-08-03

Start date

2022-09-01

Completion date

2023-03-01

Last updated

2022-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis (RA)

Brief summary

Vitamin D level and its association with disease activity in Egyptian Rheumatoid arthritis (RA) patients

Detailed description

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects about 1% of the human population. Its incidence increases between 25 and 55 years and is the most common type of chronic inflammatory arthritis . It affects joints bilaterally with synovial hyperplasia, cartilage erosion, bone destruction, and progressive loss of function . also characterized by systemic features and joint involvement. It can lead to significant morbidity and mortality so early diagnosis and proper treatment are crucial in decreasing the burden of this disease . According to the World Health Organization mortality database of 31 countries, RA accounts for almost 18% of all deaths caused by different types of arthritis and other musculoskeletal diseases, but the exact cause of RA remains unknown

Interventions

DRUGVit D

Vit D

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Both males and females in the age group of 1875 years having RA according to the American College of Rheumatology European League Against Rheumatism 2010 criteria (Meena et al., 2018). Will enrolled in this study

Exclusion criteria

* Patients with malnutrition, hepatic and renal dysfunction, hyperparathyroidism, hyperthyroidism, diabetes mellitus, and patients on Vitamin D supplementation in the past 6 months or on medications that can affect bone and Vitamin D metabolism (anticonvulsants, diuretics, and thyroxin) were excluded from this study. * Patients with overlap syndrome * known allergy to DMARDs, 1,25 dihydroxy vitamin D3 or calcium supplements

Design outcomes

Primary

Measure	Time frame	Description
prevalence of vitamin D dificency in Rheumatoid arthritis	3 years	prevalence of vitamin D dificency in Rheumatoid arthritis Egyption patients compared by healthy patients

Contacts

Primary ContactMariam Sa Farag, Master

‬mariam.samir20495@gmail.com‪0155 553 2738‬

Backup ContactPerer At Munir, Master

Peteratef662@gmail.com01553529181

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026